The effect of sitagliptin on insulin secretion in Japanese type 2 diabetic patients. - Medical Approach by Incretin in KyotO Sitagliptin Anti-diabetic Study

Department of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University0 个研究点目标入组 100 人开始时间: 2010年12月24日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Patients who could not sign informed consent for this study. 2.Patients with history of malignancy. 3.Patients with severe complications as follows: dysfunction of heart, lung, liver, kidney and pancreas and cerebral vessel disease as well as infections. 4.Patients with severe diabetic complications, such as bleeding diabetic retinopathy, diabetic nephropathy (eGFR<30), diabetic neuropathy, gangrene, ketosis, diabetic pre-coma and diabetic coma. 5.Patients during pregnancy or possible pregnant women. 6.Patients with type 2 diabetes using other antidiabetic drugs. 7.Patients with gastrointestinal symptoms such as diarrhea and vomiting. 8.Patients who are inadequate to entry this study. 9.Patients with severe frequent hypoglycemia and condition of hypoglycemia-unconsciousness. 10.Patients who are treated or will be treated with drugs which increase blood glucose such as steroids, interferon and tacrolimus.

发起方

Department of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University